• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    agilon health Reports Second Quarter 2024 Results

    8/6/24 4:00:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $AGL alert in real time by email

    Revenue increased 39% to $1.5 billion, Medicare Advantage membership increased 38% to 513,000, and total members on the agilon platform grew 40% to 645,000

    Executing targeted action plan and prioritizing profitability

    First half results reflect retroactive membership adjustments to January 1, 2024 related to agilon's termination of select contracts

    Maintains 2024 Medical Margin and Adjusted EBITDA Guidance

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced results for the second quarter ended June 30, 2024.

    "Our second quarter results were in-line with our guidance, and we are maintaining medical margin and Adjusted EBITDA guidance for the full year," said Steve Sell, chief executive officer. "We continue to make progress implementing our performance action plan which should contribute to accelerating our profitability over time and strengthening our value proposition to physicians and payers."

    Second Quarter 2024 Results:

    • Total members on the agilon platform increased to 645,000 as of June 30, 2024, comprising 513,000 Medicare Advantage members and 132,000 ACO model beneficiaries. Medicare Advantage membership increased 38%, with 6% growth in same partner geographies.
    • Select unprofitable contract terminations were made effective retroactive to January 1, 2024. This reduced membership by 17,000 members and reduced total Revenues by $110 million compared to previous guidance and had no effect on medical margin for second quarter.
    • Total revenue of $1.48 billion in the second quarter 2024 increased 39% compared to $1.07 billion in the second quarter 2023.
    • Gross profit was $32 million in the second quarter 2024 compared to $55 million in the second quarter 2023. Net loss was $31 million in the second quarter 2024 compared to $17 million in the second quarter 2023.
    • Medical margin was $106 million during the second quarter 2024, compared to $134 million for the same period 2023.
    • Adjusted EBITDA totaled a $3 million loss in the second quarter 2024 compared to earnings of $12 million for the same period in 2023.

    Key Financial and Operating Metrics ($M):

    (Second Quarter 2024 vs. 2023)

     

     

    Three Months

    Ended June 30,

     

     

    Change

     

    2024

     

    2023

     

    % YoY

    Medicare Advantage Members1

    512,800

     

    372,800

     

    38%

    ACO Model Members1, 2

    131,700

     

    87,000

     

    51%

    Total Members Live on Platform1, 2

    644,600

     

    459,800

     

    40%

    Avg. Medicare Advantage Members

    507,000

     

    373,500

     

    36%

    Total revenues

    $1,483

     

    $1,069

     

    39%

    Gross Profit

    $32

     

    $55

     

    (41%)

    Medical Margin

    $106

     

    $134

     

    (21%)

    Net (Loss) Income

    ($31)

     

    ($17)

     

    (83%)

    Adjusted EBITDA3

    ($3)

     

    $12

     

    NM

    Geography Entry Costs

    $5

     

    $19

     

    (74%)

     
    1. Membership metrics reflect end of period results.
    2. agilon's ACO model entities are not included within its consolidated financial results.
    3. agilon's ACO model entities contributed $11 million to Adjusted EBITDA during both the second quarter 2024 and 2023.

    Continued Progress on Performance Action Plan

    agilon health is making tangible progress against its targeted action plan to improve performance. This plan includes refining payor relationships, increasing engagement among PCPs to reduce variability, improving data visibility and analytics, and accelerating operating efficiency.

    agilon health continues to make progress on obtaining favorable health plan agreements across markets and payer types. The company continues to deploy structured training and local medical director engagement with PCPs. In the second quarter, this activity covered 20 markets and ~75% of PCPs in the model. agilon achieved its target of onboarding ~75% of member data into the company's financial data pipeline and expects to onboard the remaining balance through the second half of 2024. The company continues to focus on improving operating expense efficiency; platform support costs accounted for 2.8% of revenue in the second quarter, compared to the company's 3% target for 2024.

    Capital Position and Balance Sheet:

    agilon health's balance sheet as of June 30, 2024 included cash, cash equivalents and marketable securities of $408 million and total debt of $36 million. At the end of the quarter agilon health had $104 million of cash associated with the company's unconsolidated ACO model entities.

    Outlook for Fiscal Year 2024 ($M):

     

    Year Ended December 31, 2024

    Updated Guidance

    Previous Guidance

    Low

    High

    Low

    High

    Medicare Advantage Members1

    518,000

     

    520,000

     

    510,000

     

    515,000

    ACO Model Members1,2

    123,000

     

    128,000

     

    120,000

     

    125,000

    Total Members Live on Platform1

    641,000

     

    648,000

     

    630,000

     

    640,000

    Avg. Medicare Advantage Members

    513,000

     

    514,000

     

    510,000

     

    514,000

    Total Revenues

    $6,010

     

    $6,040

     

    $6,125

     

    $6,175

    Medical Margin

    $400

     

    $450

     

    $400

     

    $450

    Adjusted EBITDA3

    ($60)

     

    ($15)

     

    ($60)

     

    ($15)

    Geography Entry Costs4

    $55

     

    $45

     

    $65

     

    $55

     
    1. Membership reflects management's outlook for end of period.
    2. agilon's partnered ACO model entities are not consolidated within its financial results.
    3. Adjusted EBITDA contribution from ACO model is expected to be approximately $35 million for fiscal year 2024.
    4. Geography Entry Costs represent the corresponding expense included in the low-end and high-end of management's outlook for Adjusted EBITDA.

    Outlook for Third Quarter 2024 ($M):

     

     

    Quarter Ended

    September 30, 2024

    Low

    High

    Medicare Advantage Members1

    514,000

     

    516,000

    ACO Model Members1,2

    125,000

     

    130,000

    Total Members Live on Platform1

    639,000

     

    646,000

    Avg. Medicare Advantage Members

    511,000

     

    513,000

    Total Revenues

    $1,465

     

    $1,475

    Medical Margin

    $90

     

    $110

    Adjusted EBITDA3

    ($30)

     

    ($10)

    Geography Entry Costs4

    $19

     

    $14

     
    1. Membership reflects management's outlook for end of period.
    2. agilon's partnered ACO model entities are not consolidated within its financial results.
    3. Adjusted EBITDA contribution from ACO model is expected to be approximately $8 million for the third quarter 2024.
    4. Geography Entry Costs represent the corresponding expense included in the low-end and high-end of management's outlook for Adjusted EBITDA.

    The company has not reconciled guidance for medical margin to gross profit or adjusted EBITDA to net income (loss), the most comparable GAAP measures, and has not provided forward-looking guidance for net income (loss) in each case because of the uncertainty around certain items that may impact gross profit or net income (loss), including non-cash stock-based compensation.

    Webcast and Conference Call:

    agilon health will host a conference call to discuss second quarter 2024 results on Tuesday, August 6, 2024 at 4:30 PM Eastern Time. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 689044. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

    About agilon health

    agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups and health systems transition to a value-based Total Care Model for their senior patients. agilon provides the technology, people, capital, process, and access to a peer network of 3,000+ PCPs that allow its physician partners to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is the trusted partner in 30+ diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information visit www.agilonhealth.com and connect with us on Instagram, LinkedIn and YouTube.

    Forward-Looking Statements

    Statements in this release that are not historical factual statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "believes," "expects," "may," "will," "shall," "should," "would," "could," "seeks," "aims," "projects," "is optimistic," "intends," "plans," "estimates," "anticipates" or the negative versions of these words or other comparable terms. Examples of forward-looking statements include, among other things: statements regarding our expectations related to operating and financial results, the value of our full-risk model for primary care physicians, the acceleration of profitability over time, the strengthening of our value proposition to physicians and payers, and our long-term opportunities and strategic growth plans, expected revenue, medical costs, net income and gross profit, total and average membership, Adjusted EBITDA, Medical Margin, geography entry costs and other financial projections and assumptions, including our fiscal year and third quarter 2024 guidance. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be outside our control. These risks and uncertainties that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, but are not limited to: our history of net losses and the expectation that our expenses will increase in the future; failure to identify and develop successful new geographies, physician partners and payors, or execute upon our growth initiatives; success in executing our operating strategies or achieving results consistent with our historical performance; medical expenses incurred on behalf of our members may exceed revenues we receive; our ability to secure contracts with Medicare Advantage payors; our ability to grow new physician partner relationships sufficient to recover startup costs; availability of additional capital, on acceptable terms or at all, to support our business in the future; significant reduction in our membership; transition to a Total Care Model may be challenging for physician partners; public health crises, such as COVID-19, could adversely affect us; inaccuracy in estimates of our members' risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts; the impact of restrictive clauses or exclusivity provisions in some of our contracts with physician partners; our ability to hire and retain qualified personnel; our ability to realize the full value of our intangible assets; security breaches, cybersecurity attacks, loss of data and other disruptions to our information systems; our ability to protect the confidentiality of our know-how and other proprietary and internally developed information; reliance on our subsidiaries; Environmental, Social, and Governance issues; reliance on a limited number of key payors; the limited terms of contracts with our payors and our ability to renew them upon expiration; reliance on our payors, physician partners and other providers to operate our business; our ability to obtain accurate and complete diagnosis data; reliance on third-party software, data, infrastructure and bandwidth; consolidation and competition in the healthcare industry; the impact of changes to, and dependence on, federal government healthcare programs; uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures; regulation of the healthcare industry and our and our physician partners' ability to comply with such laws and regulations; federal and state investigations, audits and enforcement actions; repayment obligations arising out of payor audits; negative publicity regarding the managed healthcare industry generally; our use, disclosure and processing of personally identifiable information, protected health information, and de-identified data; failure to obtain or maintain an insurance license, a certificate of authority or an equivalent authorization; lawsuits not covered by insurance; changes in tax laws and regulations, or changes in related judgments or assumptions; our indebtedness and our potential to incur more debt; dependence on our subsidiaries for cash to fund all of our operations and expenses; provisions in our governing documents; ability to achieve a return on your investment depends on appreciation in the price of our common stock; the material weakness in our internal control over financial reporting and our ability to remediate such material weakness; and risks related to other factors discussed in our filings with the Securities and Exchange Commission (the "SEC"), including the factors discussed under "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which can be found at the SEC's website at www.sec.gov. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

    agilon health, inc.

    Condensed Consolidated Balance Sheets

    In thousands, except per share data

     

     

    June 30,

    2024

     

    December 31,

    2023

     

    (unaudited)

     

     

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    109,490

     

     

    $

    107,570

     

    Restricted cash and equivalents

     

    6,846

     

     

     

    6,759

     

    Marketable securities

     

    291,622

     

     

     

    380,773

     

    Receivables, net

     

    1,437,040

     

     

     

    942,461

     

    Prepaid expenses and other current assets, net

     

    39,012

     

     

     

    42,513

     

    Total current assets

     

    1,884,010

     

     

     

    1,480,076

     

    Property and equipment, net

     

    27,821

     

     

     

    27,576

     

    Intangible assets, net

     

    74,821

     

     

     

    63,769

     

    Goodwill

     

    24,133

     

     

     

    24,133

     

    Other assets

     

    152,530

     

     

     

    145,312

     

    Total assets

    $

    2,163,315

     

     

    $

    1,740,866

     

    LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

     

     

     

    Current liabilities:

     

     

     

    Medical claims and related payables

    $

    1,097,664

     

     

    $

    737,724

     

    Accounts payable and accrued expenses

     

    280,899

     

     

     

    233,182

     

    Current portion of long-term debt

     

    8,750

     

     

     

    6,250

     

    Total current liabilities

     

    1,387,313

     

     

     

    977,156

     

    Long-term debt, net of current portion

     

    27,360

     

     

     

    32,308

     

    Other liabilities

     

    72,775

     

     

     

    70,381

     

    Total liabilities

     

    1,487,448

     

     

     

    1,079,845

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

    Stockholders' equity (deficit):

     

     

     

    Common stock, $0.01 par value: 2,000,000 shares authorized; 411,447 and 406,387 shares issued and outstanding, respectively

     

    4,114

     

     

     

    4,064

     

    Additional paid-in capital

     

    2,038,540

     

     

     

    1,986,899

     

    Accumulated deficit

     

    (1,363,572

    )

     

     

    (1,326,826

    )

    Accumulated other comprehensive income (loss)

     

    (2,447

    )

     

     

    (2,298

    )

    Total agilon health, inc. stockholders' equity (deficit)

     

    676,635

     

     

     

    661,839

     

    Noncontrolling interests

     

    (768

    )

     

     

    (818

    )

    Total stockholders' equity (deficit)

     

    675,867

     

     

     

    661,021

     

    Total liabilities and stockholders' equity (deficit)

    $

    2,163,315

     

     

    $

    1,740,866

     

    agilon health, inc.

    Condensed Consolidated Statements of Operations

    In thousands, except per share data

    (unaudited)

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

     

     

     

     

     

     

     

    Revenues:

     

     

     

     

     

     

     

    Medical services revenue

    $

    1,479,579

     

     

    $

    1,067,234

     

     

    $

    3,080,774

     

     

    $

    2,120,353

     

    Other operating revenue

     

    3,179

     

     

     

    1,881

     

     

     

    6,338

     

     

     

    3,074

     

    Total revenues

     

    1,482,758

     

     

     

    1,069,115

     

     

     

    3,087,112

     

     

     

    2,123,427

     

    Expenses:

     

     

     

     

     

     

     

    Medical services expense

     

    1,374,060

     

     

     

    932,823

     

     

     

    2,817,902

     

     

     

    1,830,395

     

    Other medical expenses

     

    76,523

     

     

     

    81,716

     

     

     

    161,947

     

     

     

    165,333

     

    General and administrative (including noncash stock-based compensation expense of $18,207, $19,446, $35,116, and $33,031, respectively)

     

    69,612

     

     

     

    79,254

     

     

     

    146,034

     

     

     

    149,006

     

    Depreciation and amortization

     

    5,907

     

     

     

    4,279

     

     

     

    11,751

     

     

     

    7,233

     

    Total expenses

     

    1,526,102

     

     

     

    1,098,072

     

     

     

    3,137,634

     

     

     

    2,151,967

     

    Income (loss) from operations

     

    (43,344

    )

     

     

    (28,957

    )

     

     

    (50,522

    )

     

     

    (28,540

    )

    Other income (expense):

     

     

     

     

     

     

     

    Income (loss) from equity method investments

     

    9,955

     

     

     

    8,472

     

     

     

    15,639

     

     

     

    9,848

     

    Other income (expense), net

     

    4,841

     

     

     

    7,087

     

     

     

    10,733

     

     

     

    14,979

     

    Interest expense

     

    (1,697

    )

     

     

    (1,555

    )

     

     

    (2,981

    )

     

     

    (3,048

    )

    Income (loss) before income taxes

     

    (30,245

    )

     

     

    (14,953

    )

     

     

    (27,131

    )

     

     

    (6,761

    )

    Income tax benefit (expense)

     

    (417

    )

     

     

    (1,073

    )

     

     

    (284

    )

     

     

    686

     

    Income (loss) from continuing operations

     

    (30,662

    )

     

     

    (16,026

    )

     

     

    (27,415

    )

     

     

    (6,075

    )

    Discontinued operations:

     

     

     

     

     

     

     

    Income (loss) before gain (loss) on sales

     

    —

     

     

     

    (769

    )

     

     

    (518

    )

     

     

    5,239

     

    Gain (loss) on sales of assets, net

     

    —

     

     

     

    —

     

     

     

    (8,763

    )

     

     

    —

     

    Total discontinued operations

     

    —

     

     

     

    (769

    )

     

     

    (9,281

    )

     

     

    5,239

     

    Net income (loss)

     

    (30,662

    )

     

     

    (16,795

    )

     

     

    (36,696

    )

     

     

    (836

    )

    Noncontrolling interests' share in (earnings) loss

     

    (20

    )

     

     

    46

     

     

     

    (50

    )

     

     

    109

     

    Net income (loss) attributable to common shares

    $

    (30,682

    )

     

    $

    (16,749

    )

     

    $

    (36,746

    )

     

    $

    (727

    )

     

     

     

     

     

     

     

     

    Net income (loss) per common share, basic and diluted

     

     

     

     

     

     

     

    Continuing operations

    $

    (0.07

    )

     

    $

    (0.04

    )

     

    $

    (0.07

    )

     

    $

    (0.01

    )

    Discontinued operations

    $

    —

     

     

    $

    —

     

     

    $

    (0.02

    )

     

    $

    0.01

     

    Weighted average shares outstanding

     

     

     

     

     

     

     

    Basic

     

    411,271

     

     

     

    410,338

     

     

     

    409,152

     

     

     

    411,748

     

    Diluted

     

    411,271

     

     

     

    410,338

     

     

     

    409,152

     

     

     

    411,748

     

    agilon health, inc.

    Condensed Consolidated Statements of Cash Flows

    In thousands

    (unaudited)

     

     

    Six Months Ended June 30,

     

    2024

     

    2023

    Cash flows from operating activities:

     

     

     

    Net income (loss)

    $

    (36,696

    )

     

    $

    (836

    )

    Adjustments to reconcile net income (loss) to net cash used in operating activities:

     

     

     

    Depreciation and amortization

     

    11,751

     

     

     

    9,704

     

    Stock-based compensation expense

     

    35,116

     

     

     

    33,244

     

    Loss (income) from equity method investments

     

    (15,639

    )

     

     

    (9,848

    )

    Distributions of earnings from equity method investments

     

    3,340

     

     

     

    —

     

    (Gain) loss on sale of assets, net and impairments

     

    3,784

     

     

     

    —

     

    Other noncash items

     

    (837

    )

     

     

    (2,322

    )

    Changes in operating assets and liabilities:

     

    (67,312

    )

     

     

    (111,957

    )

    Net cash provided by (used in) operating activities

     

    (66,493

    )

     

     

    (82,015

    )

    Cash flows from investing activities:

     

     

     

    Purchase of property and equipment

     

    (6,451

    )

     

     

    (7,811

    )

    Purchase of intangible assets

     

    (17,893

    )

     

     

    (1,837

    )

    Investment in loans receivable and other

     

    (9,742

    )

     

     

    (8,468

    )

    Investments in marketable securities

     

    (12,006

    )

     

     

    (65,568

    )

    Proceeds from maturities of marketable securities and other

     

    115,747

     

     

     

    97,269

     

    Net cash paid in business combination

     

    —

     

     

     

    (44,367

    )

    Net cash provided by (used in) investing activities

     

    69,655

     

     

     

    (30,782

    )

    Cash flows from financing activities:

     

     

     

    Proceeds from equity issuances, net

     

    1,345

     

     

     

    8,802

     

    Common stock repurchase

     

    —

     

     

     

    (200,000

    )

    Repayments of long-term debt

     

    (2,500

    )

     

     

    (2,500

    )

    Net cash provided by (used in) financing activities

     

    (1,155

    )

     

     

    (193,698

    )

    Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents

     

    2,007

     

     

     

    (306,495

    )

    Cash, cash equivalents and restricted cash and equivalents from continuing operations, beginning of period

     

    114,329

     

     

     

    475,912

     

    Cash, cash equivalents and restricted cash and equivalents from discontinued operations, beginning of period

     

    —

     

     

     

    31,768

     

    Cash, cash equivalents and restricted cash and equivalents, beginning of period

     

    114,329

     

     

     

    507,680

     

    Cash, cash equivalents and restricted cash and equivalents from continuing operations, end of period

     

    116,336

     

     

     

    184,550

     

    Cash, cash equivalents and restricted cash and equivalents from discontinued operations, end of period

     

    —

     

     

     

    16,635

     

    Cash, cash equivalents and restricted cash and equivalents, end of period

    $

    116,336

     

     

    $

    201,185

    agilon health, inc.

    Key Operating Metrics

    In thousands

    (unaudited)

     

    GROSS PROFIT

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Total revenues

    $

    1,482,758

     

     

    $

    1,069,115

     

     

    $

    3,087,112

     

     

    $

    2,123,427

     

    Medical services expense

     

    (1,374,060

    )

     

     

    (932,823

    )

     

     

    (2,817,902

    )

     

     

    (1,830,395

    )

    Other medical expenses(1)

     

    (76,523

    )

     

     

    (81,716

    )

     

     

    (161,947

    )

     

     

    (165,333

    )

    Gross profit

    $

    32,175

     

     

    $

    54,576

     

     

    $

    107,263

     

     

    $

    127,699

     

    ______________________________________________________________

    (1)

    Represents physician compensation expense related to surplus sharing and other care management expenses that help to create medical cost efficiency. Includes costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. For the three months ended June 30, 2024 and 2023, costs incurred in implementing geographies were $18,000 and $7.7 million, respectively. For the six months ended June 30, 2024 and 2023, costs incurred in implementing geographies were $0.6 million and $10.0 million, respectively.

    GENERAL AND ADMINISTRATIVE COSTS, INCLUDING PLATFORM SUPPORT COSTS

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Platform support costs

    $

    41,687

     

    $

    42,041

     

    $

    87,399

     

    $

    85,333

    Geography entry costs(1)

     

    4,866

     

     

     

    11,306

     

     

     

    15,325

     

     

     

    20,556

     

    Severance and related costs

     

    868

     

     

     

    —

     

     

     

    3,283

     

     

     

    188

     

    Stock-based compensation expense

     

    18,207

     

     

     

    19,446

     

     

     

    35,116

     

     

     

    33,031

     

    Other(2)

     

    3,984

     

     

     

    6,461

     

     

     

    4,911

     

     

     

    9,898

     

    General and administrative

    $

    69,612

     

     

    $

    79,254

     

     

    $

    146,034

     

     

    $

    149,006

     

    ______________________________________________________________

    (1)

    Represents direct geography entry costs, including investments to develop and expand our platform and costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets.

    (2)

    Includes transaction-related costs.

     

    Our platform support costs, which include regionally-based support personnel and other operating costs to support our geographies, are expected to decrease over time as a percentage of revenue as our physician partners add members and our revenue grows. Our operating expenses at the enterprise level include resources and technology to support payor contracting, clinical program development, quality, data management, finance, and legal and compliance functions.

    agilon health, inc.

    Non-GAAP Financial Measures

    In thousands

    (unaudited)

     

    MEDICAL MARGIN

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Gross profit(1)

    $

    32,175

     

     

    $

    54,576

     

     

    $

    107,263

     

     

    $

    127,699

     

    Other operating revenue

     

    (3,179

    )

     

     

    (1,881

    )

     

     

    (6,338

    )

     

     

    (3,074

    )

    Other medical expenses

     

    76,523

     

     

     

    81,716

     

     

     

    161,947

     

     

     

    165,333

     

    Medical margin

    $

    105,519

     

     

    $

    134,411

     

     

    $

    262,872

     

     

    $

    289,958

     

    ______________________________________________________________

    (1)

    Gross profit is defined as total revenues less medical services expense and other medical expenses.

    ADJUSTED EBITDA

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Net income (loss)(1)

    $

    (30,662

    )

     

    $

    (16,795

    )

     

    $

    (36,696

    )

     

    $

    (836

    )

    (Income) loss from discontinued operations, net of income taxes

     

    —

     

     

     

    769

     

     

     

    9,281

     

     

     

    (5,239

    )

    Interest expense

     

    1,697

     

     

     

    1,555

     

     

     

    2,981

     

     

     

    3,048

     

    Income tax expense (benefit)

     

    417

     

     

     

    1,073

     

     

     

    284

     

     

     

    (686

    )

    Depreciation and amortization

     

    5,907

     

     

     

    4,279

     

     

     

    11,751

     

     

     

    7,233

     

    Severance and related costs

     

    868

     

     

     

    —

     

     

     

    3,283

     

     

     

    188

     

    Stock-based compensation expense

     

    18,207

     

     

     

    19,446

     

     

     

    35,116

     

     

     

    33,031

     

    EBITDA adjustments related to equity method investments

     

    1,404

     

     

     

    2,757

     

     

     

    5,306

     

     

     

    4,724

     

    Other(2)

     

    (668

    )

     

     

    (615

    )

     

     

    (5,082

    )

     

     

    (4,956

    )

    Adjusted EBITDA

    $

    (2,830

    )

     

    $

    12,469

     

     

    $

    26,224

     

     

    $

    36,507

     

    ______________________________________________________________

    (1)

    Includes direct geography entry costs, including investments to develop and expand our platform and costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. For the three months ended June 30, 2024 and 2023, (i) $18,000 and $7.7 million, respectively, are included in other medical expenses and (ii) $4.8 million and $11.3 million, respectively, are included in general and administrative expenses. For the six months ended June 30, 2024 and 2023, (i) $0.6 million and $10.0 million, respectively, are included in other medical expenses and (ii) $15.3 million and $20.6 million, respectively, are included in general and administrative expenses.

    (2)

    Includes interest income and transaction-related costs.

    agilon health, inc.

    Supplemental Financial Information

    In thousands

    (unaudited)

     

     

    Three Months Ended

    June 30, 2024

     

    Six Months Ended

    June 30, 2024

     

    Medicare

    Advantage

    (Consolidated)

     

    CMS ACO Models

    (Unconsolidated)

     

    Medicare

    Advantage

    (Consolidated)

     

    CMS ACO Models

    (Unconsolidated)

    Medical services revenue

    $

    1,479,579

     

     

    $

    446,914

     

     

    $

    3,080,774

     

     

    $

    887,074

     

    Other operating revenue

     

    3,179

     

     

     

    —

     

     

     

    6,338

     

     

     

    —

     

    Total revenues

     

    1,482,758

     

     

     

    446,914

     

     

     

    3,087,112

     

     

     

    887,074

     

    Medical services expense

     

    (1,374,060

    )

     

     

    (406,921

    )

     

     

    (2,817,902

    )

     

     

    (805,713

    )

    Other medical expenses

     

    (76,523

    )

     

     

    (22,268

    )

     

     

    (161,947

    )

     

     

    (47,673

    )

    Gross profit

     

    32,175

     

     

     

    17,725

     

     

     

    107,263

     

     

     

    33,688

     

    Other operating revenue

     

    (3,179

    )

     

     

    —

     

     

     

    (6,338

    )

     

     

    —

     

    Other medical expenses

     

    76,523

     

     

     

    22,268

     

     

     

    161,947

     

     

     

    47,673

     

    Medical margin

    $

    105,519

     

     

    $

    39,993

     

     

    $

    262,872

     

     

    $

    81,361

     

     

    Certain of our operations are not consolidated for the period presented because we do not have the ability to control certain activities due to another party's control of the entities' board of directors. Although revenues of the unconsolidated operations are not recorded as revenues by us, income (loss) from equity method investments is nonetheless a significant portion of our overall earnings. See Note 14 to the Condensed Consolidated Financial Statements in the Quarterly Report on Form 10-Q for the period ending June 30, 2024 for additional discussion on our equity method investments.

     

    In addition to providing results that are determined in accordance with GAAP, we present Medical Margin and Adjusted EBITDA, which are non-GAAP financial measures.

     

    We define Medical Margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. As our platform matures over time, we expect Medical Margin to increase in absolute dollars. However, Medical Margin per member per month (PMPM) may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to Medical Margin PMPM. We believe this metric provides insight into the economics of our capitation arrangements as it includes all medical services expense directly associated with our members' care.

     

    We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis.

     

    Gross profit is the most directly comparable GAAP measure to Medical Margin. Net income (loss) is the most directly comparable GAAP measure to Adjusted EBITDA.

     

    We believe Medical Margin and Adjusted EBITDA help identify underlying trends in our business and facilitate evaluation of period-to-period operating performance of our operations by eliminating items that are variable in nature and not considered by us in the evaluation of ongoing operating performance, allowing comparison of our recurring core business operating results over multiple periods. We also believe Medical Margin and Adjusted EBITDA provide useful information about our operating results, enhance the overall understanding of our past performance and future prospects, and allow for greater transparency with respect to key metrics we use for financial and operational decision-making. We believe Medical Margin and Adjusted EBITDA or similarly titled non-GAAP measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance. Other companies may calculate Medical Margin and Adjusted EBITDA or similarly titled non-GAAP measures differently from the way we calculate these metrics. As a result, our presentation of Medical Margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies, limiting their usefulness as comparative measures.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240806375848/en/

    Get the next $AGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGL

    DatePrice TargetRatingAnalyst
    4/25/2025$5.00Neutral → Buy
    Citigroup
    4/8/2025$8.50Mkt Perform → Outperform
    Bernstein
    1/10/2025$1.75 → $2.25Sell → Neutral
    Citigroup
    1/10/2025Hold
    Needham
    12/16/2024Neutral
    Macquarie
    12/11/2024$2.50Mkt Perform
    Bernstein
    11/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    11/8/2024Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $AGL
    Leadership Updates

    Live Leadership Updates

    See more
    • agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

      Dr. Rao to Continue to Lead Clinical Strategy and Drive Physician Network Performance Alongside agilon's Chief Clinical Officer Kevin Spencer, M.D. agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that after a comprehensive search Karthik Rao, M.D., who has served as agilon's interim chief medical officer (CMO) since February 2024, has been appointed to the permanent CMO role, effective immediately. He previously served as senior medical director and vice president, network performance, at the company. Prior to joining agilon in 2022, Dr. Rao held several roles in value-based care, including nearly a d

      7/10/24 8:00:00 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Names Jeff Schwaneke New Chief Financial Officer

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon's board, will join the Company as chief financial officer and executive vice president effective July 1, 2024. He will be a member of agilon's Executive Leadership team reporting to chief executive officer (CEO), Steve Sell. Schwaneke succeeds Timothy Bensley, who announced his retirement from agilon in early 2024. Bensley has agreed to stay on through a transition period. Schwaneke was most recently executive vice president, Health Care Enterprises,

      6/5/24 8:00:00 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health, inc. investors: Please contact the Portnoy Law Firm to recover your losses; May 28, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises agilon health, inc. (NYSE:AGL) investors that a lawsuit was filed on behalf of investors that purchased agilon securities between April 15, 2021 and February 27, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to

      5/13/24 6:31:12 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • agilon health to Participate in Bernstein's 41st Annual Strategic Decisions Conference

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will participate in the Bernstein 41st Annual Strategic Decisions Conference including a fireside chat presentation on Wednesday, May 28 at 4:30 PM Eastern Time. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering

      5/19/25 4:04:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health to Participate in BofA Securities 2025 Health Care Conference

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will participate in the BofA Securities 2025 Health Care Conference including a fireside chat presentation on Wednesday, May 14 at 1:00 PM Eastern Time. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering physicia

      4/4/25 4:15:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Sets Date to Report First Quarter 2025 Financial Results

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the first quarter 2025 after the market closes on Tuesday, May 6, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 095319. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the ca

      3/25/25 4:05:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Financials

    Live finance-specific insights

    See more
    • agilon health Sets Date to Report First Quarter 2025 Financial Results

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the first quarter 2025 after the market closes on Tuesday, May 6, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 095319. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the ca

      3/25/25 4:05:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Sets Date to Report Fourth Quarter and Full Year 2024 Financial Results

      agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health in our communities, announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Tuesday February 25, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 599648. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A

      2/10/25 4:01:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • agilon health Reports Third Quarter 2024 Results

      Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses Adjusted full year guidance reflects Q3 results and updated Q4 cost trends agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the third quarter ended September 30, 2024. "Our full-risk model enables primary care physicians to deliver high-quality c

      11/7/24 4:00:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Schwaneke Jeffrey A. bought $250,206 worth of shares (22,300 units at $11.22) and was granted 428,922 shares, increasing direct ownership by 61% to 1,130,552 units (SEC Form 4)

      4/A - agilon health, inc. (0001831097) (Issuer)

      4/3/25 7:40:25 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • CEO & President Sell Steven covered exercise/tax liability with 15,563 shares and bought 42,426 shares, increasing direct ownership by 8% to 355,310 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      3/18/25 6:42:37 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Chief Markets Officer Shaker Benjamin bought 11,786 shares and covered exercise/tax liability with 4,143 shares, increasing direct ownership by 2% to 457,058 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      3/18/25 6:41:48 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 9,331 shares, decreasing direct ownership by 0.83% to 1,121,221 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      5/30/25 8:11:00 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Director Mckenzie Diana was granted 78,724 shares, increasing direct ownership by 134% to 137,543 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      5/30/25 7:39:34 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Director Wulf John William was granted 78,724 shares, increasing direct ownership by 38% to 284,857 units (SEC Form 4)

      4 - agilon health, inc. (0001831097) (Issuer)

      5/30/25 6:32:44 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    SEC Filings

    See more
    • agilon health inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - agilon health, inc. (0001831097) (Filer)

      5/30/25 4:43:53 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

      SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

      5/13/25 11:44:13 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

      SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

      5/12/25 10:44:45 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agilon Health upgraded by Citigroup with a new price target

      Citigroup upgraded Agilon Health from Neutral to Buy and set a new price target of $5.00

      4/25/25 8:23:09 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Agilon Health upgraded by Bernstein with a new price target

      Bernstein upgraded Agilon Health from Mkt Perform to Outperform and set a new price target of $8.50

      4/8/25 9:06:22 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Agilon Health upgraded by Citigroup with a new price target

      Citigroup upgraded Agilon Health from Sell to Neutral and set a new price target of $2.25 from $1.75 previously

      1/10/25 7:25:30 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care

    $AGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by agilon health inc.

      SC 13G/A - agilon health, inc. (0001831097) (Subject)

      11/13/24 12:49:26 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by agilon health inc.

      SC 13G/A - agilon health, inc. (0001831097) (Subject)

      11/8/24 10:52:39 AM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by agilon health inc.

      SC 13G/A - agilon health, inc. (0001831097) (Subject)

      11/6/24 4:47:14 PM ET
      $AGL
      Misc Health and Biotechnology Services
      Health Care